QumulusAI, Inc.

S-1/A amended

37,172,292 shares

S-1/A amended

37,172,292 shares

QumulusAI, Inc. is registering the resale of up to 37,172,292 shares of common stock by Registered Shareholders for a direct listing on the Nasdaq Global Market. The offering involves no underwriting, with shares subject to restrictions for directors, officers, and major shareholders. The company highlights the novel nature of the direct listing, emphasizing potential volatility due to the absence of a firm-commitment underwriting. The process involves Nasdaq's Current Reference Price mechanism, with Chardan Capital Markets acting as financial advisor. The listing is contingent on Nasdaq approval, and no assurance is provided for successful listing.

S-1/A amended

QumulusAI, Inc. is registering the resale of up to 100% of its outstanding common stock by Registered Shareholders for a direct listing on the Nasdaq Global Market under the symbol 'QMLS.' The filing outlines the process for share sales post-listing, noting that shares held by directors, officers, and major shareholders are restricted for six months. The company emphasizes the novel nature of its direct listing, which lacks a traditional underwriting process, and details Nasdaq's price-setting mechanism involving Chardan Capital Markets LLC as financial advisor.

S-1/A amended

Range $3.00 to $10.80

QumulusAI, Inc. is conducting a direct listing on the Nasdaq Global Market under the symbol 'QMLS' without a traditional underwritten offering. The filing relates to the resale of up to 100% of its outstanding common stock by Registered Shareholders, with restrictions on sales by directors, officers, and large shareholders for six months post-listing. The company emphasizes the novel nature of the direct listing, the absence of an underwriter, and the volatility risks associated with Nasdaq's price-setting mechanism. The filing highlights the uncertainty of Nasdaq approval as a critical condition for the offering.

S-1 filed

Gross proceeds $0.00

QumulusAI, Inc. is registering shares of common stock for a direct listing on the Nasdaq Global Market, allowing registered shareholders to resell their shares without an underwritten offering. The filing outlines the process for listing, including the use of Nasdaq's Current Reference Price mechanism to determine the opening price, with no involvement from investment banks. The company emphasizes the risks associated with the direct listing structure, including market volatility and the uncertainty of Nasdaq approval.

DRS/A amended

QumulusAI, Inc. has filed an amended registration statement (DRS/A) for a direct listing on the Nasdaq Global Market, registering up to [•] shares of common stock for resale by Registered Shareholders. The filing outlines a novel direct listing process without underwriting, relying on Nasdaq's price-setting mechanism. Key details include restrictions on shares held by insiders, no public market prior to listing, and reliance on Chardan Capital Markets LLC as financial advisor. The offering is contingent on Nasdaq approval, with no assurance of success.

DRS filed

QumulusAI, Inc. has filed a Draft Registration Statement (DRS) on Form S-1 for a direct listing on the Nasdaq Global Market, registering up to [•] shares of common stock for resale by existing shareholders. The offering involves no underwriting, with shares to be sold via market transactions post-listing. The company, an emerging growth company, emphasizes the novel nature of its direct listing, which lacks a traditional IPO structure and involves risks related to liquidity, price volatility, and listing approval. No proceeds will flow to the company from shareholder sales.